Ziconotide (Prialt) (CPB 0712, reviewed 2026-03-11)
Summary
Intrathecal ziconotide (Prialt) is considered medically necessary for members with severe chronic pain that is intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. It is considered not medically necessary for members with a pre-existing history of psychosis, an infection at the micro-infusion injection site, uncontrolled bleeding diathesis, or spinal canal obstruction. Use for autism, epilepsy, Irukandji syndrome, migraines, primary lateral sclerosis, and stroke is considered experimental, investigational, or unproven, as is the intrathecal combination of ziconotide, morphine, and levobupivacaine for cancer-related refractory pain.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.